干扰素与芦可替尼联合治疗真性红细胞增多症和骨髓纤维化：两种药物是否比一种更好？ - Suppr

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

作者信息

Silver Richard T

机构信息

Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medicine Division of Hematology-Oncology, New York, NY, USA.

出版信息

Haematologica. 2020 Sep 1;105(9):2190-2191. doi: 10.3324/haematol.2020.256602.

DOI:10.3324/haematol.2020.256602

PMID:33054041

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7556626/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10e0/7556626/67665579a29c/1052190.fig1.jpg

相似文献

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?干扰素与芦可替尼联合治疗真性红细胞增多症和骨髓纤维化：两种药物是否比一种更好？

Haematologica. 2020 Sep 1;105(9):2190-2191. doi: 10.3324/haematol.2020.256602.

[Hematologic Malignancies/Pediatric Malignancies. I. Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera].[血液系统恶性肿瘤/儿童恶性肿瘤。一、芦可替尼治疗骨髓纤维化和真性红细胞增多症]

Gan To Kagaku Ryoho. 2016 May;43(5):530-4.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.干扰素-α2 与芦可替尼联合治疗真性红细胞增多症和骨髓纤维化的安全性和有效性。

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.

The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis.鲁索替尼对真性红细胞增多症和骨髓纤维化患者血栓形成的影响：一项荟萃分析。

Blood Coagul Fibrinolysis. 2016 Sep;27(6):648-52. doi: 10.1097/MBC.0000000000000446.

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).一项评估泊马度胺和芦可替尼用于原发性骨髓纤维化（PMF）和真性红细胞增多症/原发性血小板增多症后骨髓纤维化（post--PV/ET MF）患者的 I 期研究。

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.芦可替尼治疗的原发性或继发性骨髓纤维化或真性红细胞增多症患者的结核病和非典型分枝杆菌感染。

Int J Infect Dis. 2019 Mar;80:134-136. doi: 10.1016/j.ijid.2019.01.002. Epub 2019 Jan 11.

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.克服骨髓纤维化和真性红细胞增多症的治疗挑战：芦可替尼的作用

Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26.

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.JAK1/2抑制剂鲁索替尼改善真性红细胞增多症后骨髓纤维化伴血小板减少症患者的骨髓纤维化：1例携带JAK2外显子12突变的病例报告

Intern Med. 2017;56(13):1705-1710. doi: 10.2169/internalmedicine.56.7871. Epub 2017 Jul 1.

Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.芦可替尼可提高血小板减少性骨髓纤维化患者的血小板生成。

J Clin Oncol. 2016 Feb 10;34(5):e38-40. doi: 10.1200/JCO.2013.51.0057. Epub 2014 Jun 23.

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.芦可替尼在骨髓纤维化和真性红细胞增多症中的依从性：“RAMP”意大利多中心前瞻性研究。

Ann Hematol. 2024 Jun;103(6):1931-1940. doi: 10.1007/s00277-024-05704-0. Epub 2024 Mar 13.

引用本文的文献

Efficacy and safety of pegylated interferon in the treatment of JAK2-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study.聚乙二醇化干扰素采用剂量递减策略治疗JAK2阳性真性红细胞增多症的疗效与安全性：一项单中心回顾性研究

Front Oncol. 2025 May 14;15:1586839. doi: 10.3389/fonc.2025.1586839. eCollection 2025.

Interleukin-1β, JAK2V617F mutation and inflammation in MPNs.白细胞介素-1β、JAK2V617F突变与骨髓增殖性肿瘤中的炎症

Blood Adv. 2024 Aug 27;8(16):4344-4347. doi: 10.1182/bloodadvances.2024013528.

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.重组干扰素-β在真性红细胞增多症及相关肿瘤治疗中的应用：理论依据与前景

Cancers (Basel). 2022 Nov 9;14(22):5495. doi: 10.3390/cancers14225495.

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms.α-干扰素与炎症在治疗费城染色体阴性慢性骨髓增殖性肿瘤中的新视角

Hemasphere. 2021 Nov 18;5(12):e645. doi: 10.1097/HS9.0000000000000645. eCollection 2021 Dec.

本文引用的文献

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.芦可替尼与干扰素-α2 联合治疗真性红细胞增多症或骨髓纤维化患者：一项 II 期研究。

Haematologica. 2020 Sep 1;105(9):2262-2272. doi: 10.3324/haematol.2019.235648.

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.费城染色体阴性经典骨髓增殖性肿瘤：欧洲白血病网的修订管理建议。

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.初始分子谱对早期骨髓纤维化患者重组干扰素-α（rIFNα）治疗反应的影响

Cancer. 2017 Jul 15;123(14):2680-2687. doi: 10.1002/cncr.30679. Epub 2017 May 18.

Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.重组干扰素-α用于治疗骨髓纤维化可减轻骨髓纤维化，改善其形态，并与临床反应相关。

Mod Pathol. 2015 Oct;28(10):1315-23. doi: 10.1038/modpathol.2015.93. Epub 2015 Aug 14.

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.干扰素在真性红细胞增多症、原发性血小板增多症和骨髓纤维化治疗中的作用。

Expert Rev Hematol. 2013 Feb;6(1):49-58. doi: 10.1586/ehm.12.69.

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.聚乙二醇化干扰素-α-2a在真性红细胞增多症中可诱导完全血液学和分子反应，且毒性较低。

Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.重组干扰素-α治疗真性红细胞增多症的长期疗效

Cancer. 2006 Aug 1;107(3):451-8. doi: 10.1002/cncr.22026.

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.接受伊马替尼或α干扰素治疗的真性红细胞增多症患者的最小分子反应

Blood. 2006 Apr 15;107(8):3339-41. doi: 10.1182/blood-2005-09-3917. Epub 2005 Dec 13.

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.干扰素-α-2b对骨髓增殖性疾病的长期治疗：可行性与疗效

Cancer. 1998 Sep 15;83(6):1205-13. doi: 10.1002/(sici)1097-0142(19980915)83:6<1205::aid-cncr21>3.0.co;2-8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献